Caldaret

DB06231InvestigationalSmall molecule

Investigated for use/treatment in heart disease and myocardial infarction.

Mechanism: Cardiac damage due to the buildup of sodium (Na+) ischemia and early reperfusion leads to increased calcium (Ca2+) through the reverse mode Na+/Ca2+(NCX) ion exchanger. Caldaret is an intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exhanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR).
Curator reviewed
Primary indication: Investigated for use/treatment in heart disease and myocardial infarction.Curator reviewed
Formula / weight: C₁₁H₁₆N₂O₃S · 256.32 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyDCDFLGVJWQIRGH-UHFFFAOYSA-NSMILESCC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Caldaret, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.